Charleston, SC -- (SBWIRE) -- 09/11/2013 -- The Team of advisers at Capital Equity Report are committed to bringing you stock picks that are noteworthy and priced at a great value. We work for you and we welcome any feedback you may have to offer. Have a look at: Globalstar, Inc. (OTCMKTS:GSAT), Federal National Mortgage Association (OTCBB:FNMA), OncoSec Medical Inc (OTCMKTS:ONCS), Nutra Pharma Corp. (OTCMKTS:NPHC)
Globalstar, Inc. (OTCMKTS:GSAT) increased +4.95% and closed at $0.890 on a traded volume of 10.50 million shares, in comparison to 1.79 million shares of average trading volume. So far this year, the stock is up over +178.13%.
The company has a total market capitalization of $591.69 million and its total outstanding shares are 664.82 million. Globalstar, Inc. provides mobile voice and data communications services through satellite worldwide.
Will GSAT Continue To Move Higher? Find Out Here
Federal National Mortgage Association (OTCBB:FNMA) plunged -1.22% and closed at $1.22 on a traded volume of 5.68 million shares, whereas its average trading volume is 13.81 million shares. In the last three months, the stock is down -36.39%. The Intra-day range for the stock is $1.21 and $1.24.
Federal National Mortgage Association (Fannie Mae) provides liquidity and stability support services in the secondary mortgage market in the United States. The company securitizes mortgage loans originated by lenders in the primary mortgage market into Fannie Mae mortgage-backed securities (Fannie Mae MBS).
Has FNMA Found The Bottom and Ready To Move Up? Find Out Here
OncoSec Medical Inc (OTCMKTS:ONCS) dropped down -8.86% and closed at $0.319. So far in three months, the stock is up +12.32%. The 52-week range for the stock is $0.18 and $0.49 and during the previous trading session the stock touched its highest price at $0.35. Its introductory price for the day was $0.35, with the overall traded volume of 4.09 million shares.
OncoSec Medical Incorporated designs, develops, and commercializes novel cancer therapeutic products in the United States. Its products combine proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics, known as OMS ElectroOncology.
Why Should Investors Buy ONCS After the Recent Fall? Just Go Here and Find Out
Nutra Pharma Corp. (OTCMKTS:NPHC), after opening its shares at the price of $0.02, dropped -13.92% to close at $0.0167 for the day. The stock moved on a traded volume of 17.02 million shares, in comparison to 8.02 million shares of average trading volume.
The 52-week range for the stock is $0.0035 and $0.0445 and during the previous trading session the stock touched its highest price at $0.022. Its introductory price for the day was $0.022. Nutra Pharma Corporation, a biotechnology company, engages in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases.
Will NPHC Get Buyers Even After The Recent Rally? Find Out Here
Our team of advisers here at Capital Equity Report are committed to bringing you stock picks that are noteworthy and priced at a great value. We work for you and we welcome any feedback you may have to offer.
The disclaimer is to be read and fully understood before using our site, or joining our newsletter email list. Never invest into a stock discussed on this web site or the CapitalEquityReport.com newsletter unless you can afford to lose your entire investment.
Please consult with a certified financial advisor before making any investment decisions.
Read Full Disclaimer at: http://capitalequityreport.com/about-us/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)